Valeant’s Expansion Ambitions Leads To Allergan’s Door
Potential $50 billion deal would buttress Valeant as a top ophthalmology and dermatology drug marketer.
Potential $50 billion deal would buttress Valeant as a top ophthalmology and dermatology drug marketer.